Related Experiment Video

Updated: Jun 20, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Next generation multifunctional angiotensin receptor blockers

Theodore W Kurtz1, Uwe Klein

  • 1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA. kurtzt@labmed2.ucsf.edu

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|August 29, 2009
PubMed

Insights

Next-generation angiotensin receptor blockers (ARBs) offer multi-target approaches beyond renin-angiotensin system inhibition. These advanced ARBs aim to improve cardiovascular and metabolic health by addressing additional disease mechanisms.

Area of Science:

  • Cardiovascular Pharmacology
  • Metabolic Disease Research

Background:

  • Angiotensin receptor blockers (ARBs) effectively manage hypertension and cardiovascular disease by inhibiting the renin-angiotensin system (RAS).
  • Despite ARB treatment, many patients experience persistent cardiovascular events and metabolic issues, indicating limitations of solely targeting the RAS.
  • This highlights the need for novel therapeutic strategies that address multifactorial aspects of these conditions.

Purpose of the Study:

  • To explore the significance of multifunctional ARBs in reducing cardiovascular and metabolic risks.
  • To introduce next-generation ARBs designed to target mechanisms beyond simple AT(1) receptor blockade.
  • To review emerging ARB compounds with dual or multiple therapeutic actions.

Main Methods:

  • Literature review of current research on ARBs and novel therapeutic targets.
  • Analysis of emerging bifunctional molecules designed to modulate multiple signaling pathways.
  • Discussion of the potential benefits of ARBs with expanded pharmacological profiles.

Main Results:

  • Next-generation ARBs are being developed with capabilities beyond AT(1) receptor antagonism.
  • These advanced ARBs incorporate mechanisms such as endothelin receptor blockade, nitric oxide donation, neprilysin inhibition, and PPARgamma agonism.
  • Multifunctional ARBs show promise in addressing complex cardiovascular and metabolic pathophysiology.

Conclusions:

  • Multifunctional ARBs represent a promising advancement in cardiovascular and metabolic disease management.
  • By targeting multiple pathways, these novel agents may offer superior risk reduction compared to traditional ARBs.
  • Further research and clinical trials are essential to validate the efficacy and safety of these next-generation ARBs.

More Related Videos

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...